BGNE News
Archived Headlines
- Week ahead: IPO calendar fills up 03/11/16
- Biotechs lean heavily on insider buying to complete quasi-IPOs 02/11/16
- US IPO Weekly Recap: Two big biotechs break the ice as the first IPOs of 2016 trade up 02/05/16
- First two IPOs of 2016 trade up; IPO market continues its 3-year biotech run 02/03/16
- Chinese cancer biotech BeiGene prices IPO at $24, the high end of the range 02/03/16
See more
US IPO Weekly Recap: An active week as 7 IPOs average 16% pop
Seven deals raised a combined $1.2 billion this past week and first day returns averaged 16%. Performance was particularly strong for the healthcare space; Chinese cancer biotech Zai Lab led the pack, returning 55% on its first day,...read more
US IPO Weekly Recap: A SPAC and a Reg A+ price; two billion-dollar companies file
Two IPOs raised a combined $380 million this past week. Blank check company Capitol Investment Corp. IV led the way with a $350 million offering, and branded content curator Chicken Soup for the Soul Entertainment followed with a Reg A+ offering that raised $30...read more
Are US IPOs of Chinese companies a safe bet on the first day?
Even as the 2016 IPO market lags the prior year by deal count (34 IPOs; -53%), proceeds ($5.5B raised; -58%) and filings (49 submissions; -54%), US IPO activity of China-based companies has kept pace with 2015. Including Thursday's ...read more
Renaissance Capital's 1Q16 US IPO Market Review
The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing...read more